Bio-Techne Corporation

NasdaqGS TECH

Bio-Techne Corporation Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 455.24 M

Bio-Techne Corporation Total Non-Current Liabilities is USD 455.24 M for the quarter ending September 30, 2024, a -27.72% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Bio-Techne Corporation Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 629.86 M, a 36.35% change year over year.
  • Bio-Techne Corporation Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 461.94 M, a -5.58% change year over year.
  • Bio-Techne Corporation Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 489.24 M, a -3.77% change year over year.
  • Bio-Techne Corporation Total Non-Current Liabilities for the quarter ending September 30, 2020 was USD 508.39 M, a -23.27% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Loading...
SV Wall Street
NasdaqGS: TECH

Bio-Techne Corporation

CEO Mr. Kim Kelderman
IPO Date Feb. 9, 1989
Location United States
Headquarters 614 McKinley Place N.E.
Employees 3,100
Sector Healthcare
Industries
Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Similar companies

LQDA

Liquidia Corporation

USD 14.33

0.70%

LEGN

Legend Biotech Corporation

USD 37.31

-2.07%

UTHR

United Therapeutics Corporation

USD 354.58

0.97%

VTYX

Ventyx Biosciences, Inc.

USD 1.87

-6.97%

AKRO

Akero Therapeutics, Inc.

USD 53.85

-0.43%

APLS

Apellis Pharmaceuticals, Inc.

USD 28.49

-1.79%

PCVX

Vaxcyte, Inc.

USD 84.81

-3.97%

ASND

Ascendis Pharma A/S

USD 130.66

2.64%

ALNY

Alnylam Pharmaceuticals, Inc.

USD 274.55

1.19%

EXEL

Exelixis, Inc.

USD 32.88

-0.81%

BMRN

BioMarin Pharmaceutical Inc.

USD 62.44

-1.45%

TVTX

Travere Therapeutics, Inc.

USD 20.22

-1.17%

HALO

Halozyme Therapeutics, Inc.

USD 56.28

-0.64%

BPMC

Blueprint Medicines Corporation

USD 111.50

-0.92%

REPL

Replimune Group, Inc.

USD 13.71

-1.93%

NUVL

Nuvalent, Inc.

USD 84.85

-1.12%

StockViz Staff

February 4, 2025

Any question? Send us an email